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Cerebral cavernous malformations (CCMs) le-
sions consist of densely packed vascular sinu-
soids  lined  by  a  thin  endothelium  with  rare 
subendothelial cells and no intervening paren-
chyma (Russel and Rubinstein, 1989; Clatterbuck 
et al., 2001). Ultrastructural analysis of CCM 
lesions  showed  defective  tight  junctions  (TJ) 
between  endothelial  cells  (ECs). The  lesions 
form predominantly in the central nervous sys-
tem (CNS), but 5% of the patients also show 
lesions in the retina (Labauge et al., 2007; Riant 
et al., 2010).
The prevalence has been estimated to be up 
to 0.5% in the general population. CCM oc-
curs as a sporadic (80% of patients) or a familial 
disease (20% of patients), after an autosomal dom-
inant  pattern  of  inheritance.  Sporadic  patients 
most often have a single CCM lesion, whereas 
patients affected by a hereditary form of the 
disease have multiple lesions and show a pro-
gressive increase in lesion number over time. 
Symptoms  include  headaches,  seizures,  and   
focal  neurological  deficits  caused  by  cerebral 
hemorrhages. The major risk for patients is the 
recurrence  of  hemorrhages.  Neurosurgery  is 
the only therapy offered today; however, it is 
not  always  possible  depending  on  the  lesion   
location within the CNS.
Familial CCM disease is caused by hetero-
zygous germline mutations in any of the three 
CCM genes identified so far (CCM1/KRIT1, 
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Cerebral cavernous malformations (CCM) are vascular malformations of the central nervous 
system (CNS) that lead to cerebral hemorrhages. Familial CCM occurs as an autosomal 
dominant condition caused by loss-of-function mutations in one of the three CCM genes. 
Constitutive or tissue-specific ablation of any of the Ccm genes in mice previously estab-
lished the crucial role of Ccm gene expression in endothelial cells for proper angiogenesis. 
However, embryonic lethality precluded the development of relevant CCM mouse models. 
Here, we show that endothelial-specific Ccm2 deletion at postnatal day 1 (P1) in mice 
results in vascular lesions mimicking human CCM lesions. Consistent with CCM1/3 involve-
ment in the same human disease, deletion of Ccm1/3 at P1 in mice results in similar CCM 
lesions. The lesions are located in the cerebellum and the retina, two organs undergoing 
intense postnatal angiogenesis. Despite a pan-endothelial Ccm2 deletion, CCM lesions are 
restricted to the venous bed. Notably, the consequences of Ccm2 loss depend on the devel-
opmental timing of Ccm2 ablation. This work provides a highly penetrant and relevant CCM 
mouse model.
© 2011 Boulday et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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use to analyze the role of the CCM proteins during cerebral 
angiogenesis and CCM pathophysiology.
In this study, to bypass embryonic lethality, we deleted the 
Ccm2 gene in the mouse in an inducible, EC-specific manner. 
Postnatal day 1 (P1) deletion of Ccm2 resulted in vascular   
lesions that are strikingly similar to human CCM lesions in 
the cerebellum and retina. Using the same strategy, P1 dele-
tion of Ccm1 or Ccm3 led to similar cerebellar and retinal   
lesions. We showed that CCM2 lesion development is restricted 
to the venous bed. We also demonstrated the existence of a 
time window for the effects of Ccm2 deletion, related to a   
developmental stage with intense angiogenesis. Here, we de-
scribe a relevant mouse model for CCM disease with com-
plete penetrance and fast development of the disease allowing 
us to follow the lesion development.
RESULTS
Endothelial-specific Ccm2 deletion at P1 results in vascular 
malformations mimicking human CCM lesions in the CNS
To bypass the embryonic lethality previously encountered in 
the Tie2Cre;Ccm2 KO mouse model (Boulday et al., 2009), 
we crossed Ccm2 floxed mice with the endothelial-specific, 
tamoxifen-inducible  Cdh5(PAC)-CreERT2  mice  (Wang   
et al., 2010). Rosa26-Stopfl-LacZ reporter mice were used   
to monitor the tamoxifen-induced Cre/Lox recombination 
(Soriano, 1999). As assessed by XGal staining, high recombi-
nation efficiency was obtained after tamoxifen treatment   
(Fig. S1, A–F). Unless otherwise mentioned, the genotype of 
Ccm2-ablated mice (iCCM2 for inducible CCM2 KO) was 
Cdh5(PAC)-CreERT2;  Ccm2  fl/Del;  Rosa-Stopfl-LacZ  (see 
Materials and methods for details of mouse breeding).
Animals were tamoxifen injected at P1 and were analyzed 
at different time points, from P6 through 3 wk of age (Table I). 
The estimated survival median for iCCM2 animals calculated 
by the Kaplan-Meier test is 17 d (with a P < 0.001 of sig-
nificance  for  survival  compared  with  controls;  Fig.  1 A).   
At P8, all iCCM2 animals were alive and grossly undistin-
guishable from controls. They did not show any significant 
difference in weight (4.14 ± 0.6 g for iCCM2 versus 4.51 ± 
0.7 g for controls). However, from P6 onward, we were able 
to distinguish the iCCM2 animals upon dissection of the 
brain (for 80% of the P6-P7 iCCM2 and 100% from P8 
onward) and a clear aggravation of the vascular phenotype 
over time was observed (Fig. S2 A). P1 deletion of Ccm2   
resulted in the development of CCM lesions within the CNS 
CCM2/MGC4607, and CCM3/PDCD10; Craig et al., 1998; 
Laberge-le Couteulx et al., 1999; Liquori et al., 2003; Denier   
et al., 2004; Bergametti et al., 2005). Recently, a “two-hit” 
mechanism has been demonstrated in human ECs within   
the  CCM  lesions  (Gault  et  al.,  2005; Akers  et  al.,  2009;   
Pagenstecher et al., 2009).
The three CCM genes encode scaffold proteins without 
any sequence homology. In the recent past, in vitro data ob-
tained in different cell types identified numerous CCM protein 
partners that form complexes involved in various intracellular 
signaling pathways (Faurobert and Albiges-Rizo, 2010). Con-
sistent  with  their  involvement  in  CCM  pathogenesis,  the 
three CCM proteins can interact in a cytosolic ternary com-
plex, where CCM2 acts as a bridge between CCM1 and 
CCM3 (Hilder et al., 2007). However, the in vivo functions 
of this ternary complex remain unclear.
When associated with the integrin 1-binding protein 
ICAP-1, KRIT1 shuttles from the cytosol to the nucleus; its 
function there remains to be determined. CCM2 interaction 
with KRIT1 modulates KRIT1 trafficking by sequestering 
KRIT1 in the cytoplasm (Zawistowski et al., 2005). KRIT1 
is a Rap1 effector and stabilizes the endothelial cell–cell junc-
tions (Glading et al., 2007). Recently, physical interaction be-
tween KRIT1 and CCM2 was proven to be required for 
CCM protein localization at endothelial cell–cell junctions 
(Stockton et al., 2010). KRIT1 has also been involved in vas-
cular lumenization and polarization of the endothelial tube in 
vitro (Lampugnani et al., 2010).
Several  studies  have  provided  new  insights  into  CCM 
protein functions in vitro, including cytoskeletal remodeling, 
cell–cell junction homeostasis, lumen formation, and polar-
ization. However, it remains to be clarified which protein 
complexes and signaling pathways are relevant in vivo, and 
how the loss of function of any of the three CCM proteins 
might explain the etiology of the CCM disease. To this aim, 
relevant mouse models for the CCM disease are needed to 
understand  the  molecular  mechanisms  involved  in  lesion 
pathogenesis. Moreover, relevant mouse models reproducing 
CCM lesions would allow development of preclinical thera-
peutic studies (Leblanc et al., 2009; Yadla et al., 2010).
Over the past few years, several groups reported constitu-
tive or tissue-specific KO mice for all three  CCM genes. 
Homozygous Ccm1-deficient mice die at midgestation with 
defects in the vascular structure and impaired arterial mor-
phogenesis (Whitehead et al., 2004). We and others have 
shown  that  endothelial-specific  ablation  of  Ccm2  severely   
affects embryonic angiogenesis, leading to lethality at mid-
gestation (Boulday et al., 2009; Whitehead et al., 2009). In   
contrast, neuronal-specific and smooth muscle cell–specific 
deletion of Ccm2 does not affect the vascular development 
(Whitehead et al., 2009). In a recent publication, He et al. 
(2010) reported similar results using constitutive or tissue-
specific  deletion  of  Ccm3  in  mice. Together,  those  studies 
demonstrated that endothelial expression of the CCM pro-
teins is crucial for proper angiogenesis. However, the embry-
onic lethality of these previous mouse models limited their 
Table I.  Number of iCCM2 analyzed after P1 deletion
Age of 
analysis
Total numbers  
of iCCM2
iCCM2 with cerebral CCM lesionsa/ 
total number of iCCM2
P6-7 12 10/12
P8-10 30 30/30
P11-15 10 10/10
P16-19 4 4/4
aVisible lesions upon dissection.JEM Vol. 208, No. 9 
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Ccm2 deletion in the mouse retina mimic the CCM retinal 
lesions found in patients (Fig. 1 D, right).
We used the same gene targeting strategy to invalidate 
endothelial Ccm1 or Ccm3 in mice. Tamoxifen-induced dele-
tion of Ccm1 or Ccm3 at P1 resulted in CCM malformations 
in the CNS of all iCCM1 and iCCM3 animals analyzed (n = 4 
in each group). The CCM1 and CCM3 lesions were compa-
rable to the lesions obtained after Ccm2 deletion in terms of 
location (within the cerebellum and at the periphery of the 
retina) and phenotype (Fig. S3).
We established a relevant mouse model for the human 
CCM with a complete penetrance and a fast development of 
CCM lesions from single to multiple hemorrhagic caverns 
(Fig. 1 B and Fig. S2, C–F). Moreover, P1 deletion of any of 
the three Ccm genes resulted in a similar phenotype according 
to what is established for the human CCM disease.
Endothelial cell–cell junctions are altered in CCM2 KO cells 
in vitro and in CCM2 lesions
To investigate whether part of the phenotype could be related 
to  altered  endothelial  cell–cell  junctions,  we  analyzed  the   
expression and organization of junctional proteins in ECs   
in vitro and in vivo in cerebellar vessels of 
iCCM2 mice.
We  abrogated  CCM2  expression  by 
treating  ECs  derived  from  Ccm2fl/fl  mice 
with  TAT-Cre  recombinase  (Fig.  S4  A).   
of all iCCM2 animals. Interestingly, the lesions were exclu-
sively located in the cerebellum (Fig. 1 B). Histology showed 
cerebellar lesions composed of dilated vessels full of blood 
cells (Fig. 1 B, bottom). In more severe cases, lesions form 
multiple caverns, sometimes with evident signs of hemor-
rhage (Fig. 1 B, right). The mouse CCM lesions phenocopy 
lesions found in human CCM patients (Fig. 1 D, left). At P8, 
lesions of different severity were found in the same iCCM2 
animal, from small vessel dilations to large caverns (Fig. S2, B–F). 
From P9 onward, some iCCM2 animals were found dead in 
their cage. When possible, analysis of these animals before 
death revealed extensive cerebral hemorrhages, located mostly 
around the multiple caverns composing CCM lesions but also 
scattered all over the brain (Fig. 1 B, right; and not depicted). 
In  addition  to  CCM  lesions,  Ccm2  deletion  at  P1  in  the 
mouse induced dilation of vessels from the pial surface of the 
cerebellum (Fig. 1 B, middle).
Because 5% of familial CCM patients show vascular   
lesions in the retina, we analyzed the retinal vessels in iCCM2 
mice. All iCCM2 animals showed CCM vascular malforma-
tions located at the periphery of the retinal vascular plexus in 
both eyes (Fig. 1 C). Again, the vascular lesions obtained after 
Figure 1.  Endothelial Ccm2 deletion at P1  
results in CCM malformations mimicking the 
human CCM lesions in the cerebellum and in the 
retina. All animals were injected at P1 with 10 µl 
tamoxifen (equivalent to 20 µg) and dissected at the 
indicated time. Genotypes of inducible CCM2 KO 
(iCCM2) and control animals were respectively 
Cdh5(PAC)-CreERT2; Ccm2Del/fl and Cdh5(PAC)-Cre-
ERT2; Ccm2+/fl. (A) Kaplan-Meier survival curve from 
the control group (blue line, n = 110) and the iCCM2 
group (dotted red line, n = 56). Circles represent cen-
sored animals, which were sacrificed for analysis.  
(B) Control and iCCM2 mouse brains upon dissection 
(top) and after H&E staining (bottom; n = 6 in each 
group from 4 different litters, analyzed between P11 
and P19). CCM malformations, located in the cerebel-
lum of iCCM2 animals, are composed by single or 
multiple caverns (asterisks) with extensive hemor-
rhage (black arrows) around the juxtaposed vascular 
cavities. Note the dilation of meningeal vessels in the 
iCCM2 (yellow arrow). (C) Control and iCCM2 mouse 
retinas at P13 upon dissection (left and middle) and 
after isolectin-B4 staining (right, n = 7 in each group 
from 4 different litters, analyzed between P11 and 
P15). (D) Mouse lesions phenocopy human CCM  
lesions. (left) Histology of the cerebral lesions in 
mouse and human. (right) Mouse retina upon dissec-
tion and human retinal angiography Bars: 2 mm  
(B, top); 500 µm (C and D, mouse retina); 100 µm  
(B [bottom] and D [mouse cerebellum]).1838 New model of cerebral cavernous malformations | Boulday et al.
We then analyzed endothelial junction organization in vivo 
in iCCM2 brain vasculature (Fig. 2). Staining of junctional 
components supported data obtained in cultured ECs. Indeed, 
claudin-5 or ZO.1 were correctly expressed in peri-lesion 
vessels, but strongly reduced in abnormally dilated and hem-
orrhagic CCM lesions (Fig. 2 B). In addition, the AJ protein 
VE-cadherin appeared to be disorganized and was not clearly 
concentrated  at  intercellular  endothelial  cell–cell  contacts 
within the lesion, as compared with normal cerebral vessels in 
iCCM2 animals (Fig. 2 C).
Overall, these data indicate that CCM2 is required for 
proper cell–cell junction architecture in ECs in vitro and that 
CCM2  deletion  in  vivo  results  in  impaired  EC  junction   
architecture in CCM2 lesions.
To investigate the mechanism of the strong reduction in 
claudin-5  expression  upon  CCM2  ablation,  we  evaluated   
the major regulators of claudin-5 expression, including the   
Akt–FoxO1  signaling  pathway  (Brunet   
et  al.,  1999;  Burgering  and  Kops,  2002; 
Zhang et al., 2002; Daly et al., 2004; Taddei   
et al., 2008), the transcription factor Sex- 
determining region Y-box-18 (SOX18), and 
the  ETS  ternary  complex  ELK3  (Fontijn   
et  al.,  2008).  Phosphorylation  of Akt  was   
enhanced  in  confluent  CCM2  KO  ECs 
compared with control ECs, accompanied 
by  a  strong  phosphorylation  of  FoxO1   
(Fig. S5 A). These data excluded Akt–FoxO1 
pathway involvement in claudin-5 reduction 
in CCM2-null ECs. In contrast, SOX18 ex-
pression was found to be reduced by 50% by 
quantitative RT-PCR in CCM2 KO versus 
control ECs, whereas ELK3 expression was 
not modified (Fig. S5 B). This result supports 
the idea that alteration in SOX18 expression 
In the absence of CCM2, ECs lost correct organization of 
both TJ and adherens junctions (AJ; Fig. S4, B–D). Expres-
sion of the TJ component claudin-5 was essentially absent 
in  CCM2  KO  ECs  and  was  undetectable  at  junctions. 
ZO.1 also presented a discontinuous and weak staining at 
cell–cell  contacts,  whereas  JAM-A  and Afadin  appeared 
diffuse on the cell membrane (Fig. S4 D). AJ components 
such as VE-cadherin, -catenin, and -catenin were sig-
nificantly reduced by CCM2 deletion and presented a dot-
ted, faint, and irregular staining at junctions (Fig. S4 D and 
not depicted). Conversely, plakoglobin, another member   
of  the  catenin  family,  was  strongly  increased,  whereas 
PECAM1 was unchanged (Fig. S4 C). Thus, in CCM2-null 
ECs, the overall composition and organization of junctions 
is strongly altered. In addition, endothelial monolayer per-
meability in the absence of CCM2 was significantly in-
creased (Fig. S4 E).
Figure 2.  Ccm2 deletion alters AJ and TJ organi-
zation in CCM lesions. Analysis of cell–cell junc-
tions in CCM2 malformations on frozen sections of 
iCCM2 brain. For all immunofluorescence experi-
ments, cell nuclei are visualized with DAPI (blue). 
Data are representative of 3 independent observa-
tions (n = 5 in each group, from 2 different litters). 
(A) H&E staining (left) and confocal microscopy analy-
sis showing vessels stained using anti-PECAM1 (red, 
right). (B) Co-staining of the vessels using PECAM1 
staining (red) and the TJ components (green) using 
claudin-5 (top) and ZO.1 (bottom). Claudin-5 and 
ZO.1 are normally expressed in peri-lesion vessels 
(arrowheads), whereas they are strongly down- 
regulated in abnormally dilated and hemorrhagic 
vessels of the lesion (dotted area). (C) VE-cadherin 
staining (red) of the endothelium lining lesion and 
peri-lesion vessels. (right) Magnification of the boxed 
area. Pink arrows indicate VE-cadherin expressed 
outside of the junctions. Bars: 200 µm (A); 100 µm 
(B); 60 µm (C, top); 4 µm (C, bottom and right).JEM Vol. 208, No. 9 
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2006; Fruttiger, 2007). Within the first week of life a vascular 
plexus develops at the inner surface of the retina, from the 
central retina toward the periphery. At this stage, the strict   
could be one of the mechanisms responsible for the down-
regulation of claudin-5 in the absence of CCM2.
The Wnt–-catenin pathway is not involved in CCM2 lesion 
development in vivo
-Catenin participates in the formation and stabilization of 
cadherin-based  adhesion  by  forming  a  connection  to  the   
actin cytoskeleton (Dejana, 2010). -Catenin is also a key ele-
ment of the canonical Wnt (wingless and Int-1) signaling that 
promotes the nuclear localization of -catenin by blocking 
the -catenin destruction complex. Binding of -catenin to 
cadherins  can  antagonize  Wnt  signaling  by  sequestering   
-catenin  at  the  membrane. Alteration  of AJ  promotes   
-catenin nuclear translocation and the subsequent activation   
of T cell factor (TCF)/lymphoid enhancer factor (LEF) tran-
scriptional complexes. KRIT1 is localized at the endothelial 
cell–cell junction and can be co-precipitated with -catenin 
(Glading et al., 2007). Depletion of endothelial KRIT1 in   
vitro has been described to induce -catenin delocaliza-
tion  from  the  membrane  to  the  nucleus  leading  to  in-
creased  -catenin  transcriptional  activity  (Glading  and 
Ginsberg, 2010).
Interestingly, in CCM2 KO ECs in vitro, we also observed 
a delocalization of -catenin from the membrane to the   
nucleus, suggesting -catenin activation (unpublished data). 
However, TCF/LEF--catenin transcriptional activity, as de-
tected using the TOPFlash reporter, which includes six TCF-
binding sites, was not significantly modified in CCM2-null 
cells compared with controls (Fig. 3 A), suggesting that the 
Wnt–-catenin pathway is not disregulated in CCM2-null 
ECs in vitro.
To  investigate  whether  the Wnt–-catenin  signaling 
pathway is involved in vivo in the CCM pathogenesis, we 
assessed the -catenin transcriptional activity in the absence 
of CCM2 in mice. Animals were crossed with the BAT-Gal 
reporter mouse (see Materials and methods for mating de-
tails),  which  drives  -galactosidase  expression  under  the 
control of multimerized TCF/LEF binding sites for acti-
vated nuclear -catenin. iCCM2; BAT-Gal mice were in-
jected at P1 with tamoxifen to ablate Ccm2. Consistent with 
the previous study by Maretto et al. (2003), the -catenin 
signaling  was  activated  in  the  mouse  cerebellum  at  P8   
(Fig. 3, B–I). We found a similar activation of the -catenin 
signaling in controls or iCCM2 cerebellum, mostly located 
in the Purkinje cell layer, and in some ECs within the white 
matter. In contrast, the endothelium lining the CCM mal-
formations did not show any evidence of -catenin signal-
ing pathway activation at P8, neither in the cerebellum nor 
in the retina (Fig. 3, G–I; and not depicted), suggesting an 
absence of Wnt–-catenin pathway involvement in iCCM2 
lesions at the time of analysis.
CCM lesions specifically affect the venous bed  
and not the arterial compartment
Retinal vessels develop after birth in the mouse, after a very 
well defined and organized pattern (Dorrell and Friedlander, 
Figure 3.  Ccm2 deletion has no significant effect on Wnt–-
catenin signaling pathway in CCM2 KO ECs in vitro and in iCCM2 
lesions. (A) TCF/LEF--catenin transcriptional activity in CCM2 WT and 
null ECs in vitro was determined by transfecting CCM2 WT and KO ECs 
with the TOP-TK-Luc or the FOP-TK-Luc reporter constructs (containing 
WT or mutant Tcf/Lef binding sites, respectively, and a basal TK promoter, 
upstream a luciferase gene). Columns are means ± SD of triplicates from 
a representative experiment out of three performed. (B-I) Animals were 
bred with the BAT-Gal reporter mouse to assess -catenin activation (see 
Materials and methods for breeding details). All animals were injected 
with tamoxifen at P1. XGal staining, performed on control and iCCM2 
cerebellum, is shown (n = 8 in each group, from 3 different litters). White 
arrows show the CCM lesions in iCCM2 animals (in C, E, and G). In F–I, 
H&E staining was performed on cerebellum sections, after XGal staining. 
The box in G is magnified in I. H shows a CCM lesion composed of  
multiple juxtaposed caverns. Gcl, granular cell layer; ml, molecular layer; 
pcl, Purkinje cell layer; wm, white matter. Bars: 1 mm (B and C); 500 µm 
(D and E); 100 µm (F and G); 50 µm (H and I).1840 New model of cerebral cavernous malformations | Boulday et al.
early stages to determine herein the natural history of the 
CCM lesion over time. We followed lesion development in 
the retina with an isolectin-B4 staining (Fig. 5). As early as 
P7, the vascular plexus was thicker at the venous leading 
edge of the retina in iCCM2 animals. Quantification of 
the vascular coverage at the venous leading edge showed a 
29% increase in iCCM2 retinas compared with controls 
(Fig. 5 B; 0.56 ± 0.01 in controls versus 0.76 ± 0.01 in 
iCCM2; P = 0.0004; n = 4). By P9, the main veins were 
dilated in iCCM2 animals with abnormal capillaries at the 
periphery of the vascular plexus. In 3-wk-old control mice, 
the retinal vasculature was fully established, with 3 distinct 
plexuses. In contrast, at the periphery of iCCM2 retinas,   
it was not possible to distinguish different vascular plex-
uses. The vasculature from the lesion was composed by 
bubblelike vascular structures packed together. A 2,000-kD 
intracardiac  FITC-Dextran  injection  confirmed  that   
those abnormal vascular structures were lumenized (un-
published data).
To investigate the mechanisms of the increase in diameter 
of iCCM2 retinal vessels at P7, we assessed whether EC pro-
liferation was altered in the absence of CCM2. Using a phos-
pho-histone-3 staining, we could not detect any significant 
increase in EC proliferation in iCCM2 compared with con-
trols at P6 (Fig. 5 C). These data suggest that EC proliferation 
is not the primary event leading to CCM malformations and 
does not contribute to the early vascular phenotype induced 
by Ccm2 deletion.
alternation between arteries (thin and straight with avascular 
spaces surrounding arteries) and veins (larger and more sinu-
ous) can easily be distinguished using an isolectin-B4 staining 
(Fig. 4 A). Analyzing retina from 1-wk-old P1-ablated iCCM2 
animals, we observed that CCM malformations at the periph-
ery of the iCCM2 retinas were clearly restricted to veins and 
the surrounding capillaries (Fig. 4 A).
In utero Ccm2 deletion led to vascular anomalies in the 
cerebral hemispheres, affecting cerebral rhinal veins and the 
surrounding capillaries (Fig. 4 B). In contrast, middle cerebral 
arteries remained normal. To further confirm that the arterial 
compartment is not affected by CCM lesion, we compared 
vessels from mice mated with either the Rosa26-Stopfl-LacZ 
reporter  mouse  (to  visualize  all  the  vessels),  or  with  the   
artery-specific EphrinB2tlacZ reporter mouse (Fig. 4, A [right] 
and C; see Materials and methods for breeding details). XGal 
stainings showed that endothelium of the retinal and cerebral 
CCM lesions did not express the arterial-specific EphrinB2 
marker. In addition, P1 deletion also resulted in dilation of 
vessels running along the cerebellar folia at the meningeal 
surface corresponding to dorsal cerebellar veins (Fig. 1 B; 
Nonaka et al., 2002).
Collectively, our results showed that Ccm2 deletion affects 
the venous bed and leads to capillary-venous malformations.
Natural history of CCM lesions
A great advantage of animal models is the possibility to 
explore the etiology of the vascular malformations at very 
Figure 4.  CCM lesions are capillary- 
venous and do not affect the arterial 
compartment. (A) Analysis at P9 or P12 of 
the retinal vasculature from control or iCCM2 
animals using vascular isolectin-B4 staining 
(left and middle, n = 25 in each group ana-
lyzed between P8 and P10), after XGal stain-
ing (right, n = 4 in each group, from 2 
different litters). Tamoxifen-induced Ccm2 
deletion was performed at P1. Arteries (A) are 
thin and normal in iCCM2 retinas, whereas 
veins (V) are dilated in iCCM2 animals. Aster-
isks show CCM lesions developing at the pe-
riphery of the retina. (B) Lateral view of 
cerebral hemispheres of control and iCCM2 
embryos dissected at E19.5 (n = 8 in each 
group, from 4 different litters). Ccm2 deletion 
was performed at E14.5. Vascular anomalies 
affect the caudal rhinal vein (crhv) and the capil-
laries surrounding in the iCCM2 animals. The box 
in the middle panel is magnified in the image on 
the right. (C) Analysis of the cerebellar vessels at 
P10 and P12 after XGal staining on whole brain 
(left) and after a H&E staining (right). Animals 
were crossed with either the Rosa26-Stopfl-LacZ 
reporter mouse or the artery-specific Ephrin-
B2tlacZ reporter mouse. Results shown are repre-
sentative of at least four animals in each group, 
from two different litters. Bars: 1 mm (A and B, 
left and middle); 500 µm (B [right] C [left]); 100 
µm (A, right); 50 µm (C, right).JEM Vol. 208, No. 9 
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Collectively, our data on Ccm2 deletion during embryo-
genesis, the postnatal period, and at 3 wk of age strongly sug-
gested  that  the  effects  of  Ccm2  deletion  on  CCM  lesion 
development were restricted to key time points temporally 
related to the angiogenic process.
DISCUSSION
In the present paper, we used an inducible, EC-specific dele-
tion of the Ccm2 gene, to bypass the embryonic lethality   
encountered after constitutive or endothelial-specific Ccm2 
ablation  (Boulday  et  al.,  2009; Whitehead  et  al.,  2009). 
The pathological consequences of Ccm2 ablation  
are restricted to key time points temporally related  
to intense angiogenesis
Ccm2 deletion at P1, a time of intense angiogenesis in the 
mouse retina and cerebellum (Yu et al., 1994; Plate, 1999; 
Acker et al., 2001; Dorrell and Friedlander, 2006) resulted in 
CCM lesions in both organs within a week after deletion. To 
assess whether the effect of Ccm2 deletion is temporally cor-
related to the angiogenic process we compared deletion of 
Ccm2 at P1 with deletion either at 3 wk of age, after establish-
ment  of  retinal  and  cerebellar  vessels  (Acker  et  al.,  2001;   
Dorrell  and  Friedlander,  2006),  or  during  embryogenesis, 
when cerebral angiogenesis is at an intensive stage (Fig. 6;   
Yu et al., 1994; Plate, 1999). Tamoxifen-induced recombina-
tion efficiency was confirmed for the different protocols   
used (Fig. S1).
Ccm2 deletion in 3-wk-old animals did not lead to any 
gross  cerebrovascular  phenotype,  as  observed  on  iCCM2 
brains upon dissection at 2 mo of age (n = 4; Fig. 6 A, middle). 
Histology performed on iCCM2 brains did not reveal any 
vascular lesion or any sign of hemorrhage in the cerebral 
hemispheres and cerebellum (unpublished data). Moreover, 
isolectin-B4 stainings of retinal vessels showed similar vascu-
lature in iCCM2 and control animals (Fig. 6 B). These data 
show that Ccm2 deletion at 3 wk did not lead to CCM in the 
mouse, suggesting that endothelial Ccm2 is dispensable for 
mature vessels.
We  and  others  have  reported  that  endothelial-specific 
Ccm2 deletion resulted in early embryonic death around em-
bryonic day 10.5 (E10.5; Boulday et al., 2009; Whitehead   
et al., 2009). In the present work, tamoxifen-induced endo-
thelial-specific Ccm2 deletion was performed at E14.5 to by-
pass the early embryonic lethality. At E19.5, iCCM2 mice 
were distinguishable from their hemorrhagic skin (unpub-
lished data). Upon dissection, iCCM2 brains showed vascular 
anomalies located on the cerebral hemispheres with irregular 
and tortuous rhinal cerebral veins surrounded by abnormal 
capillaries (Fig. 6 A, right; n = 8).
To get some insight into the tightness of the time-window 
for Ccm2 deletion-mediated vascular effects, Ccm2 was ab-
lated  at  different  postnatal  time  points.  P4  inactivation   
(n = 4) resulted within 10 d after induction, in a milder vas-
cular phenotype compared with P1 inactivation, which was 
still clearly visible upon dissection (Fig. S6 B, to be com-
pared with Fig. S2 A). Histology of the brain showed single 
isolated caverns located within the cerebellum, without sign 
of hemorrhage (Fig. S6 E). Lesions were also observed at the 
periphery of the retinal vasculature (Fig. S6 H). After P8-   
(n = 5) and P15- (n = 2) Ccm2 ablation, no obvious vascular 
phenotype was detected upon dissection in the cerebellum, 
at P16 and P34, respectively (Fig. 6 D and not depicted). How-
ever, histology analysis revealed vessel dilations that might 
precede CCM lesion development (Fig. S6 F). Isolectin-B4 
stainings also showed vessel dilations at the periphery of the 
P8-ablated iCCM2 retinas (Fig. S6 J).
Figure 5.  Natural history of the CCM lesions. (A) Retinal CCM lesion 
development from P7 to P16. The vasculature at the periphery of the 
retina on controls or iCCM2 animals is shown after isolectin-B4 staining. 
C, central retina; p, peripheral retina. Data are representative of at least 
50 animals in each group, analyzed between P6 and P19. (B) Quantifica-
tion of the vascular coverage at the venous leading edge of the plexus in 
the retina at P7. Data are expressed as vascular area ± SEM (isolectin- 
B4–positive area, relative to total retinal area analyzed; n = 4 in each 
group, from 2 different litter; 6–8 fields analyzed per retina). (C) Quantifi-
cation of the EC proliferation in control or iCCM2 retinas at P6, assessed 
by total number of phospho-histone 3–positive ECs per retina ± SD  
(n = 6 in each group, from 3 different litters). Bars, 100 µm.1842 New model of cerebral cavernous malformations | Boulday et al.
to increase the rate of somatic muta-
tion of CCM genes and obtain vascu-
lar lesions in heterozygous Ccm1+/ or 
Ccm2+/ mice. On a tumor repres-
sor Trp53-null  background,  30%  of   
the Ccm1+/ mice developed lesions 
(Plummer et al., 2004), but the fre-
quency  of  early  onset  malignancies 
was a limitation of this model. With a 
similar approach, 50% of the Ccm1+/ 
mice with a mismatch repair complex 
null background (Msh2/; Ccm1+/) 
developed  lesions  (McDonald  et  al., 
2011). No lesion was obtained in the 
Msh2/;Ccm2+/ mice.
This  sensitized  mouse  model,  as 
well as the model from Louvi et al. 
(2011), has the advantage of progress-
ing slowly, with a relative normal lifetime for the animal. In 
addition, according to what is thought to happen in human, 
lesion development in the heterozygous McDonald’s model 
occurs as a stochastic event throughout the brain (McDonald 
et al., 2011). In contrast, in the model described herein, a very 
efficient loss of both Ccm2 alleles is obtained in ECs, provid-
ing a more aggressive model. iCCM2 animals after P1-induction 
show a rapid onset of the disease, with lesion development 
restricted to some specific locations of the CNS, followed by 
an early death caused at least in part by severe hemorrhages 
within the CNS. However, our results using later postnatal 
Ccm2 deletion (Fig. S6) suggested that a milder mouse model, 
useful for long term studies, could be obtained that might   
allow lesion development within the brain hemispheres. This 
will be the subject for further analysis. Finally, it would be 
unrealistic to expect one animal model to fully recapitulate a 
human phenotype and we believe that the different CCM 
mouse models available so far will be complementary for 
mechanistic exploration.
In our study, AJ and TJ organization was strongly affected 
in CCM2-deficient ECs in vitro and in the CCM2 lesions in 
vivo, consistent with the impaired TJs described in human 
CCM lesions. CCM2 deletion caused complex changes in AJ 
and TJ  organization,  which  included  down-regulation  of 
Early post-natal deletion of Ccm2 resulted in vascular lesions 
strikingly recapitulating human CCM lesions in the brain as 
well as in the retina, in 100% of Ccm2-deleted animals. In this 
robust and relevant mouse model for the human CCM dis-
ease, we showed that CCM lesions affect only the venous bed 
and that CCM development is restricted to key time periods 
temporally related to intense angiogenesis.
In the past few years, different groups working in the field 
of CCM in vivo models concluded to a vascular, EC-specific, 
autonomous function of the 3 Ccm genes (Hogan et al., 2008; 
Boulday et al., 2009; Whitehead et al., 2009; He et al., 2010). 
Recently, a paper challenged those results showing CCM-like 
lesions after neuroglial-specific loss of Ccm3. In contrast to 
what was previously published, Louvi et al. (2011) demon-
strated a cell autonomous effect of Ccm3 in astrocytes, result-
ing in increased cell proliferation and cell survival, as well as a 
cell nonautonomous effect, resulting in a vascular phenotype. 
This data suggest that Ccm genes play a role in vascular and 
non vascular cells within the CNS, pointing out the impor-
tance of the communication between cells composing the 
neurovascular unit, which may partly explain the CNS re-
striction of the CCM lesions.
Another approach to obtain a mouse model for human 
CCM has been developed using genetic sensitizers, attempting 
Figure 6.  Timing of ablation determines 
endothelial response to CCM2 loss. Control 
and iCCM2 animals were injected with tamox-
ifen to delete Ccm2 at P1 (left, n = 25 in each 
group, analyzed between P8 and P10), at  
3 wk of age (middle, n = 4 in each group, 
from 3 different litters) or at E14.5 during 
gestation (right, n = 8 from 4 different litters). 
(A) Control and iCCM2 brains upon dissection.  
(B) Isolectin-B4 staining on control and 
iCCM2 retinas. Note the CCM lesion in the  
P1-induced animal (asterisks). V, vein. Bars:  
2 mm (A, left and middle); 500 µm (A [right] 
and B [left]); 100 µm (B, right).JEM Vol. 208, No. 9 
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Within the brain and the retina, CCM lesions affect only 
the venous bed. This is consistent with what is observed in 
human retinal CCM lesion when using retinal angiography. 
The bubblelike vascular structures composing the CCM reti-
nal lesion are the last vessels to be filled up by the fluorescent 
dye, suggesting that lesions are composed by pocket-like cap-
illaries connected to the venous system. In zebrafish, Ccm1 or 
Ccm2 knockdown using morpholinos did not affect dorsal 
aorta and intersomitic vessel development, but resulted in ab-
normal morphogenesis with major dilation of the posterior 
cardinal vein and the caudal vein (Hogan et al., 2008). In our 
study, mechanisms explaining the venous restriction of CCM2 
lesions remain to be elucidated. The venous-specific effect of 
CCM2 ablation cannot be explained by a difference in the 
timing of excision that would affect a vascular bed with a later 
development, because veins and arteries of the superficial vas-
cular plexus develop concomitantly in the retina (Dorrell and 
Friedlander, 2006; Fruttiger, 2007). We then excluded a differ-
ence in recombination efficiency between veins and arteries. 
As assessed by XGal staining on retinas or cerebral hemi-
spheres,  P1-tamoxifen–induced  recombination  was  clearly   
affecting arteries and veins to the same extent (Fig. S1, A and 
B). Another trivial explanation would be a venous restriction 
of Ccm2 expression during late embryogenesis and the post-
natal period. In a previous work, we detected a moderate la-
beling for all three Ccm transcripts in the heart, arterial, and 
venous large vessels by E14.5, decreasing at late embryogenic 
stages (Petit et al., 2006). To further address this issue, we com-
pared CCM2 mRNA and protein expression in mesenteric 
arteries and veins. No significant difference in Ccm2 gene ex-
pression level was observed in these two vascular beds at the 
perinatal period (unpublished data). CCM2 protein expres-
sion was also confirmed in both types of vessels (unpublished 
data). The  venous  specificity  of  CCM  lesions  could  also   
reflect a different level of TJ component expression (i.e., clau-
din-5 expression) in veins versus arteries. However, claudin-5 
expression, evaluated by quantitative RT-PCR was similar in 
mesenteric arteries and veins (unpublished data). Thus, addi-
tional work is needed to clarify what differs between veins 
and arteries that could explain the specific response of venous 
EC to Ccm2 deletion.
The main characteristic feature of affected veins at early 
stages of lesion development in retinas of the iCCM2 mice 
was an increase in the size of the veins. To understand the 
mechanisms of this venous dilation, we analyzed EC prolifer-
ation before lesion formation. We did not find any enhance-
ment in EC proliferation, suggesting that proliferation is not 
the primary event leading to lesions. This is consistent with 
what was found by other groups in the mouse as well as in the 
zebrafish  (Hogan  et  al.,  2008;  McDonald  et  al.,  2011).  In 
iCCM2  cerebellum,  the  endothelium  lining  the  already 
formed CCM lesions (single or multicavernous) did not show 
any increase in cell proliferation compared with endothelium 
from controls, as assessed by stainings for the proliferation- 
associated nuclear protein Ki67 at P8 and P14 (Fig. 2 J and 
not depicted). Our results contrast with other data, showing 
junctional components and alteration of their distribution at 
intercellular  contacts.  Surprisingly,  endothelial  cell–cell TJs 
were maintained in the Msh2/; Ccm1+/ mouse model as 
assessed by electronic microscopy (McDonald et al., 2011). 
The apparent discordance between this model and our data 
may come from the different approaches used by the two 
groups. In our model, we cannot exclude that, even though 
we observed a down-regulation and alteration of some AJ and 
TJ components using immunostaining approaches, the TJ   
ultrastructure could be preserved. Previous studies (Whitehead 
et al., 2009; Stockton et al., 2010) showed that in CCM2- 
deficient  ECs,  cortical  actin  cytoskeleton  was  severely  af-
fected. This effect required the association of CCM2 with 
CCM1/Krit. Data presented here add to these observations 
and show that deletion of CCM2 causes complex changes in 
AJ and TJ organization, which include down-regulation of 
junctional components and alteration of their distribution   
at  intercellular  contacts.  In  a  previous  paper,  we  showed   
(Lampugnani et al., 2010) that similar junctions’ alterations 
could also be observed in CCM1-depleted ECs, further sup-
porting  the  idea  of  a  physical  and  functional  interaction   
between CCM1 and CCM2. One of the most striking effects 
of CCM2 depletion observed in our study was the strong re-
duction of claudin-5 expression, which is likely the cause of 
altered TJ organization. This effect may explain, to a good ex-
tent, the defect in permeability control of CCM2 KO ECs in 
vitro and in vivo (Fig. S4; Stockton et al., 2010). Furthermore, 
as already mentioned, TJ are severely affected in the vascular 
lesions of CCM patients. Genetic deletion of claudin-5 is 
known to be associated to defects in blood–brain barrier (Morita 
et al., 1999), which leads to death immediately after birth.
Another functional consequence of alterations in AJ or TJ 
architecture is defective cell polarity. We previously reported 
that Ccm1 silencing altered VE-cadherin and AJ organization 
and inhibited the localization of the polarity complex at cell–
cell junctions (Lampugnani et al., 2010). As a consequence, 
the polarized expression of apical (podocalyxin) and basal 
(collagen IV) proteins was affected. In this study, although 
junctions are altered in vivo in CCM2 lesions, apical and basal 
proteins seem to be correctly distributed (Fig. S2 H). It is rea-
sonable that because CCM1, but not CCM2, also directly in-
teracts  with  integrins  and  modulates  their  functions,  this 
additional property may be required for cell polarity (Zovein 
et al., 2010).
Our  results  clearly  showed  that  despite  pan-endothelial 
Ccm2 ablation, CCM lesions did not affect all vascular beds. 
CCM lesions developed only in the cerebellum and the retina 
after P1 ablation. At the time of analysis, other highly vascular-
ized organs, such as the heart and lungs, did not show evidence 
of CCM lesions upon dissection, even though Cre-mediated 
recombination was confirmed in those organs (unpublished 
data). Thus, our data clearly demonstrate that loss of Ccm2 is not 
sufficient to induce CCM lesions. In addition to the complete 
endothelial absence of CCM2, additional factors, possibly spe-
cific for the neurovascular microenvironment, might be neces-
sary to cause the CCM disease.1844 New model of cerebral cavernous malformations | Boulday et al.
approaches to obtain mouse models for the CCM disease. All 
these very recent complementary in vivo studies show simi-
larities  but  also  differences,  most  likely  linked  to  distinct 
methodological approaches, which will be useful to decipher 
the mechanisms of CCM development.
In this study, we describe a relevant and robust mouse 
model for CCM disease with a complete penetrance in the 
CNS. We believe this model to be of importance in better 
deciphering  molecular  mechanisms  involved  in  the  CCM 
pathogenesis. Moreover, the rapid onset of the disease in the 
iCCM2 mouse model makes it particularly suitable for thera-
peutic preclinical evaluation, especially for a fast first screen-
ing of novel agents targeting lesion genesis. Indeed, prevention 
of lesion development/progression/bleeding, or induction of 
lesion regression are now the real challenge to pursue for the 
CCM disease (Yadla et al., 2010).
Herein, analysis of the iCCM2 model suggests that the 
loss of Ccm2 is required and sufficient for the development of 
CCM lesions but only in a restricted spatial and temporal 
manner. We propose that, within an appropriate time window, 
a pro-angiogenic stimulus in the neurovascular unit micro-
environment provides a permissive signal for venous EC from 
the CNS to eventually form CCM lesions.
MATERIALS AND METHODS
In  vivo  tamoxifen-induced  deletion. Tamoxifen (Sigma-Aldrich) was   
diluted in sunflower oil-10% ethanol at 10 mg/ml, and subsequent dilutions 
were performed in sunflower oil when necessary. For postnatal deletion, pups 
were injected at P1 with a single intragastric injection of 20 µg tamoxifen. 
Deletion at 3 wk of age was performed by repeated i.p. injections of 1 mg 
tamoxifen for 4 consecutive days. For deletion during embryogenesis,   
pregnant females were injected once i.p. with 1 mg tamoxifen at E14.5, and 
a cesarean was performed at E19.5.
Mouse lines. The strategy used to target the Ccm2 gene in mice (Ccm2 
floxed and Ccm2 deleted alleles) was previously described (Boulday et al., 
2009). Ccm1 and Ccm3 floxed mice were made by Taconic. The Cdh5(PAC)-
CreERT2  mouse  line  was  previously  reported  (Wang  et  al.,  2010). The 
Rosa26-Stopfl-LacZ (Soriano, 1999), EphrinB2tlacZ (Wang et al., 1998), and 
BAT-Gal (Maretto et al., 2003) mice have been purchased from The Jackson 
Laboratory. Mice were all bred on a C57BL/6 background.
To obtain the iCCM2 mice, the Cdh5(PAC)-CreERT2 mice were first 
bred with the Ccm2+/Del animals. The Cdh5(PAC)-CreERT2; Ccm2+/Del mice 
were then crossed with Rosa26-Stopfl-LacZ; Ccm2fl/fl animals. Thus, unless 
otherwise mentioned, the genotype of iCCM2 animals and controls were as 
follows: Cdh5(PAC)-CreERT2; Ccm2fl/Del; Rosa26-Stopfl-LacZ and Cdh5(PAC)-
CreERT2; Ccm2fl/+; Rosa26-Stopfl-LacZ.
EphrinB2tlacZ and BAT-Gal mice were bred with Ccm2fl/fl animals before 
be crossed with Cdh5(PAC)-CreERT2; Ccm2+/Del mice. All procedures de-
scribed in this study were in full accordance with the Institutional Animal 
Care and Use Commitee “Lariboisiere-Villemin” (Committee number 9, 
Paris, France).
Cell  culture. Mouse lung ECs were derived from lungs of 3-mo-old 
Ccm2 fl/fl mice (Boulday et al., 2009) and immortalized as previously de-
scribed (Dong et al., 1997; Balconi et al., 2000). Conditional deletion of 
Ccm2 in vitro was obtained using TAT-Cre fusion protein which is known 
to  promote  the  nuclear  translocation  of  Cre  recombinase  (Peitz  et  al., 
2002). As a control, cells were treated either with buffer or with an inactive 
form of TAT-Cre. Sparse ECs were washed with HyQ ADCF mAb me-
dium (Thermo Fisher Scientific) and treated with 100 µg/ml TAT-Cre for 
an  increase  in  proliferation  of  EC  lining  multiple  mature   
caverns  as  compared  with  single,  early  cavernous  lesions   
(McDonald et al., 2011). It is possible that the relatively short 
median survival in our mouse model may be a limit for ana-
lyzing  EC  proliferation  in  mature,  multicavernous  CCM   
lesions. Interestingly, loss of Ccm1 in zebrafish resulted in im-
paired EC morphology rather than increase in EC prolifera-
tion, with a progressive spreading and thinning of the ECs 
forming the dilated vessel (Hogan et al., 2008). We do hy-
pothesize that such a mechanism could explain the pheno-
type described in our CCM2 mouse model.
In this paper, we showed that the timing of Ccm2 deletion 
(E14.5, P1, and 3 wk of age) defines the cerebral (or retinal) 
EC response to CCM2 loss. We first excluded differences in 
tamoxifen-induced recombination efficiency that could ex-
plain the disparate temporal and spatial responses to Ccm2  
deletion.  XGal  staining  confirmed  a  high  recombination   
efficiency at E14.5, P1, and 3 wk of age, in all the cerebral and 
retinal vessels (Fig. S1, A–F). Mice induced at 3 wk, after vessel 
development, did not develop CCM lesion in the CNS. In 
contrast, mice induced at P1 showed CCM lesions in the cere-
bellum and the retina, whereas late in utero Ccm2 deletion 
elicits  vascular  malformations  in  the  cerebral  hemispheres.   
In those two situations, the location of CCM lesions in the 
CNS corresponds to specific places undergoing intense angio-
genesis at the time of deletion (Plate, 1999; Acker et al., 2001; 
Dorrell and Friedlander, 2006). Thus, our results comparing 
the different timing of Ccm2 deletion strongly suggest that 
angiogenesis  might  be  the  extra  trigger  leading  to  CCM   
lesion development. Interestingly, in human CCM patients, 
the number of lesions increases significantly with age, particu-
larly after 50 yr old (Denier et al., 2006; Labauge et al., 2007). 
In addition, it has been shown that angiogenesis can occur in 
human adult brain in response to cerebral ischemia (Beck and 
Plate, 2009). We speculate that an increase in CCM lesion 
number over 50 yr old may be related to proangiogenic stimuli 
that may be caused by hypoxic events that occur with aging.
The mechanisms of this restricted temporal CCM com-
petence are thus far unknown. In some aspects, it is reminis-
cent of the previously reported restricted temporal cystogenic 
competence of renal epithelial cells. The autosomal dominant 
polycystic kidney disease is characterized by a progressive in-
crease in renal tubular diameter followed by multiple cysts 
formation. A key postnatal developmental switch has been in-
volved in this cystogenic process and has been related to ab-
normal  planar  cell  polarity  signaling  (PCP;  Fischer  et  al., 
2006;  Piontek  et  al.,  2007;  Karner  et  al.,  2009; Verdeguer   
et al., 2010). PCP controls, through the coupling of cell divi-
sion and morphogenesis, the growth and the size of the nor-
mal renal tube. Interestingly, in the normal developing retinal 
vasculature, orientation of mitosis along the vessel axis was 
also reported (Zeng et al., 2007), suggesting that vessel growth 
is determined by PCP.
While this manuscript was in revision, two other studies 
were published (Chan et al., 2011; Cunningham et al., 2011) 
that independently validated the use of inducible Ccm KO JEM Vol. 208, No. 9 
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Immunofluorescence was analyzed using a Nikon Eclipse 80i micro-
scope or by confocal microscopy (TCS-SP2-AOBS; Leica).
Statistics. Student’s two-tailed nonpaired t test was used to determine sta-
tistical significance for in vitro analysis. The significance level was set at   
P < 0.05. Kaplan-Meier test was used to determine survival curve of the 
iCCM2 animals versus controls.
Online supplemental material. Fig. S1 shows the analysis of tamoxifen-
induced recombination. Fig. S2 shows additional analysis of CCM2 lesions in 
the cerebellum. Fig. S3 shows the cerebellar and retinal CCM lesions ob-
tained after Ccm1 and Ccm3 ablation at P1. Fig. S4 shows the analysis of AJ 
and TJ junctions in vitro in CCM2 KO ECs. Fig. S5 shows the analysis of 
molecular regulators of claudin-5 expression in vitro in CCM2 KO ECs. Fig. S6 
shows the analysis of impact of the postnatal timing for Ccm2 ablation on the 
vascular  phenotype  severity.  Online  supplemental  material  is  available  at 
http://www.jem.org/cgi/content/full/jem.20110571/DC1.
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